Could removing the main tumor boost targeted therapy in advanced lung cancer?

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 118 adults with stage III-IV cancer who have not had prior treatment will be randomly assigned to receive either surgery plus osimertinib or osimertinib alone. The goal is to see if the combination approach improves outcomes like progression-free survival and quality of life.